Skip to main content

Table 1 Missable doses and subsequent adherence.

From: Modelling imperfect adherence to HIV induction therapy

Drug (units)

R i(μM)

Ï„(days)

T 1/2 (hours)

R 1 (μM)

R 2 (μM)

maximum missable days (theoretical)

minimum subsequent days (theoretical)

Abacavir (ABC)

12

1/2

15

10-1.0269

10-0.0269

3

7

Didanosine (ddI)

4.65

1/2

25

10-1.2218

10-0.2218

5

7.5

Emtricitabine (FTC)

7.2

1

39

10-0.9788

100.0212

6

17

Lamivudine (3TC)

6

1/2

20

10-1.1249

10-0.1249

3.5

8.5

Stavudine (d4T)

2.144

1/2

7.5

10-1.6383

10-0.6383

1

2.5

Tenofivir (TDF)

1.184

1

60

10-1.5229

10-0.5229

10

24

Zidovudine (ZDV)

4.24

1/3

7

10-1.6021

10-0.6021

1.33

2.67

Delavirdine (DLV)

26.6

1/3

5.8

10-1.4559

10-0.4559

1.67

2.67

Efavirenz (EFV)

12.9

1

45

10-0.8356

100.1644

9

22

Nevirapine (NVP)

7.5

1/2

27

10-1.0088

10-0.0088

5

12.5

  1. Summary of data and theoretical results for reverse transcriptase inhibitors used for FDA-approved triple-drug therapy. All results are calculated with a mutant that exhibits 10-fold resistance to the drug. The decay rate d r was calculated using the formula d r = 24 log(2)/T 1/2, where T 1/2 is the half-life. The last two columns are the number of doses that may be missed before significant drug resistance emerges and the number that must subsequently be taken to return to within 0.01 μM of perfect adherence. We used the intracellular half-life for each drug, if known. Data for Column 1 was taken from [41–48], and data from Columns 2 and 3 were taken from the Department of Health and Human Services 2008 Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents [37]
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us